Recent research published in Obesity Reviews raises important questions regarding the nutritional implications of using medications like Ozempic and Wegovy. Led by Dr. Marie Spreckley from the University of Cambridge, the study highlights a lack of robust evidence on how nutritional counseling impacts calorie consumption, body composition, and protein intake among patients using these treatments.
Understanding GLP-1 Weight Loss Medications
Medications such as semaglutide and tirzepatide, marketed under names like Ozempic, Wegovy, and Mounjaro, mimic the effects of glucagon-like peptide-1 (GLP-1), a hormone that is released post-meal. These drugs effectively suppress appetite, enhance feelings of satiety, and mitigate cravings for food.
Due to these mechanisms, users often experience a calorie reduction of 16-39%, making these medications a powerful tool for those struggling with obesity. However, researchers point out that there has been minimal investigation into how these drugs influence overall diet quality, protein consumption, or micronutrient intake. Evidence suggests that up to 40% of the weight lost during treatment can come from lean body mass, including muscle.
The Importance of Nutritional Support
Dr. Adrian Brown, an NIHR Advanced Fellow at UCL's Centre of Obesity Research and a lead author of the study, emphasizes the changes in eating behaviors caused by these medications.
"Obesity management drugs work by reducing appetite and promoting fullness, leading to decreased food intake. This can significantly benefit individuals with obesity, aiding in weight loss and improving health outcomes," he stated.
"However, without proper nutritional support from healthcare professionals, there is a genuine risk that reduced food consumption may lead to inadequate dietary quality, potentially depriving individuals of essential proteins, fibers, vitamins, and minerals necessary for overall health."
Public Recommendations Versus Private Use
The National Institute for Health and Care Excellence (NICE) advises that semaglutide should only be prescribed for weight management to individuals who meet certain criteria, such as a BMI of at least 35.0 kg/m2 and accompanying health conditions like type 2 diabetes or cardiovascular disease. Under NHS prescriptions, these medications are intended to be part of a comprehensive program that promotes a calorie-restricted diet and increased physical activity.
However, many individuals acquire these medications outside of the NHS framework. Currently, around 1.5 million people in the UK are using GLP-1 drugs, with approximately 95% obtaining them privately. In these cases, nutritional guidance and follow-up support are often lacking.
Nutrition Guidance Lagging Behind Usage
Dr. Spreckley indicates that the rise in GLP-1 therapy usage has outpaced the availability of nutritional care.
"The adoption of GLP-1 receptor agonists has surged in a short timeframe, yet the nutritional support for users has not kept up. Many individuals receive little to no structured guidance on maintaining diet quality, protein intake, or micronutrient adequacy while experiencing significant appetite suppression," she noted.
"If nutritional care is not integrated with treatment, there is a risk of exchanging one health issue for another, leading to avoidable nutritional deficiencies and muscle mass loss. This represents a missed opportunity to facilitate long-term health alongside weight loss." Low levels of vital vitamins and minerals can lead to fatigue, compromised immune function, hair loss, and osteoporosis. Additionally, loss of lean mass can increase susceptibility to weakness, injuries, and falls.
Need for Further Research
The research team identified only 12 studies that explored nutritional aspects in conjunction with treatments like semaglutide or tirzepatide. These studies varied in their dietary advice and measurement of nutrition outcomes, often lacking standardized methods. Consequently, the researchers found it challenging to establish definitive conclusions regarding optimal support for individuals using weight loss medications.
As the usage of these drugs continues to grow, practical guidance becomes increasingly necessary. The researchers propose learning from nutritional care protocols used post-weight loss surgery, as these procedures result in similar appetite and intake reductions.
Applying Bariatric Nutrition Principles
Dr. Cara Ruggiero, a co-author from the MRC Epidemiology Unit at the University of Cambridge, believes established post-surgery nutritional strategies could address current gaps.
"While GLP-1 receptor agonists are becoming more prevalent, there remains a significant lack of structured nutritional guidance. In the meantime, we can utilize established post-bariatric nutrition principles. Our previous research underscores the importance of prioritizing nutrient-dense foods, including high-quality protein, distributed evenly across meals to help preserve lean mass during periods of appetite suppression and rapid weight loss."
Current evidence does not support strict low-fat diets alongside these medications. However, some observational studies indicate that users often consume high levels of total and saturated fats, suggesting a need for tailored guidance on fat intake in line with national dietary recommendations.
Meal timing has also been infrequently evaluated in clinical trials. Nevertheless, researchers recommend that smaller, more frequent meals may alleviate side effects like nausea, making the drugs easier to tolerate, especially at the beginning of treatment.
Incorporating Patient Experiences in Future Research
The research team stresses the importance of including the experiences of those using these medications in future studies. Gaining insights into what types of information and support patients find most beneficial could enhance real-world care.
To this end, the researchers initiated AMPLIFY (Amplifying Meaningful Perspectives and Lived experiences of Incretin therapy use From diverse communitY voices). This project aims to delve into how individuals navigate the use of next-generation weight loss drugs in their daily lives.
"These medications are revolutionizing obesity treatment, yet we know very little about their impact on daily life, including shifts in appetite, eating habits, well-being, and overall quality of life," Dr. Spreckley remarked. "Our focus is particularly on engaging communities that have historically been underrepresented in obesity research to help shape the future of treatment." The research received funding from the National Institute for Health and Care Research (NIHR), with additional backing from the Medical Research Council and the NIHR UCLH Biomedical Research Centre.
